Select your Market
Financial results for Q3 2025
Guidance for 2025
| Q3 2025 (in € billion) | Total change (in %, compared to Q3 2024) | Organic change (in %, compared to Q3 2024) |
|---|---|---|---|
Group net sales | 5.3 | 1.0 | 5.2 |
EBITDA pre | 1.7 | 3.1 | 8.8 |
Life Science sales | 2.2 | 1.4 | 5.9 |
Healthcare sales | 2.2 | 3.2 | 4.6 |
Electronics sales | 0.9 | –5.2 | 4.8 |
”We delivered solid organic growth across all three business sectors, illustrating the resilience of our diversified portfolio against significant external headwinds.”
Our CFO Helene von Roeder comments on the Q3 2025 results.
Detailed information about the development of our business in the third quarter of 2025.
Downloads for the Media
Press Releases
Strong performance by Process Solutions, Rare Diseases and Semiconductor Solutions.
2025/11/13
Our Q4 2025 results will be published on March 5, 2026, at 7 a.m. (CET). Our press conference will take place at 10:00 a.m. (CET), and the conference call for analysts at 2 p.m. (CET).
Our Q1 2026 results will be published on May 13, 2026, at 7 a.m. (CET). Our conference call for the media will take place at 9:30 a.m. (CEST), and the conference call for analysts at 2 p.m. (CEST).
